Also known as packed-cell volume (PCV) test, hematocrit test is used to measure the percentage of Red Blood Cells (RBCs) in the blood. The major function of the RBCs is to carry blood throughout the body. The test is usually performed to diagnose various diseases such as anemia, leukemia, lymphoma, congenital heart disease, and others. The test determines the elevation in the percentage of normal RBCs which is 38.8%-50% in men and 34.9%-44.5% in women. The hematocrit test is one of the tests included under complete blood count (CBC) test.
Cardiovascular diseases, cancer, and kidney diseases are increasing the economic burden of various developing and developed nations across the globe. The market for hematocrit test is driven by rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, and others along with changing lifestyle, and increasing demand for diagnostic devices for cardiovascular diseases. However, limited number of trained personnel has restrained the growth of the market. However, the high cost of diagnosis and treatment of cardiovascular diseases also restrains the growth of the market. As per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the overall prevalence of Chronic Kidney Disease (CKD) in the general population across the globe is nearly 14%. However, the growth of the market is restrained by the inaccurate or misleading result of the test and unawareness about hematocrit test in the diagnosis of the disease.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5553
The Global Hematocrit Test Market is expected to Grow at a CAGR of 4.5% during the forecast period.
Regional Analysis:
The Americas hold the largest market share in the hematocrit test due to increasing demand for technologically advanced hematology analyzers and test kits. Additionally, the presence of major market players also influences the growth of the market in the U.S. followed by Canada. Kidney disease is one of the major cause of mortality and morbidity in the Americas, thus boosting the market growth. Prevalence of cardiovascular disease and kidney diseases further accelerate the market growth. In South America, the market exhibits better growth opportunities due to the development of healthcare industry in recent years.
In Europe, the prevalence of diabetes, a major risk factor for heart disease is increasing in major economies such as Germany, thereby signifying the need for diagnostics services. Germany, France, and the U.K are the major contributors to the market growth in Europe with key players focusing on product differentiation and quality. Furthermore, the development of medical device industry and increasing awareness about early diagnosis of chronic diseases such as cancer is driving the market growth. Moreover, extensive research and development activities in the field of hematology, and the emergence of new market players in medical device industry determine the market growth.
In the Asia Pacific region, Japan, China, and India are the largest contributors to the market growth. Increasing prevalence of chronic diseases such as cardiovascular diseases, cancer, and kidney disease are the major driver for the market growth. The rapid growth of healthcare market and extensive demand for diagnostic services further fuel the growth of the market.
In the Middle East & Africa, the United Arab Emirates, Saudi Arabia, and Kuwait hold the least share of the global market due to lack of knowledge about diagnostic tests for chronic diseases and low technologically advanced devices. Whereas, the African region is expected to witness moderate growth in the market.
Segmentation:
The global hematocrit test market is segmented on the basis of product, indication, devices, and end-user.
On the basis of the product, the market is segmented into the analyzer, hematocrit test meter, and others.
On the basis of the indication, the market is segmented into anemia, leukemia, lymphoma, congenital heart disease, kidney tumor, and others.
On the basis of end-user, the market is segmented into hospitals & clinics, diagnostic centers, and others.
Key Players:
Some of key the players in the market are Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Siemens AG (Germany), Beckman Coulter, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Horiba, Ltd. (Japan), Mindray Medical International Limited (China), Boule Diagnostics AB (Sweden), Nihon Kohden Corporation (Japan), Sysmex Corporation (Japan), and others.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/hematocrit-test-market-5553
No comments:
Post a Comment